Literature DB >> 27667662

Antibodies to major histocompatibility complex class II antigens directly prime neutrophils and cause acute lung injury in a two-event in vivo rat model.

Marguerite R Kelher1,2, Anirban Banerjee2, Fabia Gamboni2, Cameron Anderson2, Christopher C Silliman1,2,3.   

Abstract

BACKGROUND: Transfusion-related acute lung injury (TRALI) is a significant cause of mortality, especially after transfusions containing antibodies to major histocompatibility complex (MHC) class II antigens. We hypothesize that a first event induces both 1) polymorphonuclear neutrophils (PMNs) to express MHC class II antigens, and 2) activation of the pulmonary endothelium, leading to PMN sequestration, so that the infusion of specific MHC class II antibodies to these antigens causes PMN-mediated acute lung injury (ALI). STUDY DESIGN AND METHODS: Rats were treated with saline (NS), endotoxin (lipopolysaccharide [LPS]), or cytokines (interferon-γ [IFNγ], macrophage colony-stimulating factor [MCSF], tumor necrosis factor-α [TNFα]); the PMNs were isolated; and the surface expression of the MHC class II antigen OX6 and priming by OX6 antibodies were measured by flow cytometry or priming assays.
RESULTS: A two-event model of ALI was completed with NS, LPS, or IFNγ/MCSF/TNFα (first events) and the infusion of OX6 (second event). Compared with NS incubation, rats treated with either LPS or IFNγ/MCSF/TNFα exhibited OX6 PMN surface expression, OX6 antibodies primed the formyl-methionyl-leucyl phenylalanine (fMLF)-activated respiratory burst, and PMN sequestration was increased. OX6 antibody infusion into LPS-incubated or IFNγ/MCSF/TNFα-incubated rats elicited ALI, the OX6 antibody was present on the PMNs, and PMN depletion abrogated ALI.
CONCLUSION: Proinflammatory first events induce PMN MHC class II surface expression, activation of the pulmonary endothelium, and PMN sequestration such that the infusion of cognate antibodies precipitates TRALI.
© 2016 AABB.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27667662      PMCID: PMC5787352          DOI: 10.1111/trf.13817

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  63 in total

1.  Polymorphonuclear neutrophils in Wegener's granulomatosis acquire characteristics of antigen presenting cells.

Authors:  C Iking-Konert; S Vogt; M Radsak; C Wagner; G M Hänsch; K Andrassy
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

2.  TRALI associated with HLA class II antibodies.

Authors:  María Varela; Antoni Mas; Núria Nogués; Angels Escorsell; Roberto Mazzara; Miguel Lozano
Journal:  Transfusion       Date:  2002-08       Impact factor: 3.157

3.  Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies.

Authors:  Ulrich J H Sachs; Wiebke Wasel; Behnaz Bayat; Rainer M Bohle; Katja Hattar; Heike Berghöfer; Angelika Reil; Jürgen Bux; Gregor Bein; Sentot Santoso; Norbert Weissmann
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

4.  Interference with TRALI-causing anti-HLA DR alloantibody induction of human pulmonary microvascular endothelial cell injury by purified soluble HLA DR.

Authors:  M Nishimura; S Hashimoto; M Satake; H Okazaki; K Tadokoro
Journal:  Vox Sang       Date:  2007-07       Impact factor: 2.144

5.  Crosstalk between inflammation, iron metabolism and endothelial function in Behçet's disease.

Authors:  Rita Oliveira; Patricia Napoleão; João Banha; Eleonora Paixão; Andreia Bettencourt; Berta Martins da Silva; Dina Pereira; Filipe Barcelos; Ana Teixeira; José Vaz Patto; Ana Maria Viegas-Crespo; Luciana Costa
Journal:  Clin Hemorheol Microcirc       Date:  2014       Impact factor: 2.375

6.  Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury.

Authors:  M Nishimura; S Hashimoto; M Takanashi; H Okazaki; M Satake; K Nakajima
Journal:  Transfus Med       Date:  2007-04       Impact factor: 2.019

7.  Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium.

Authors:  Christopher C Silliman; David J Elzi; Daniel R Ambruso; Rene J Musters; Christine Hamiel; Ronald J Harbeck; Andrew J Paterson; A Jason Bjornsen; Travis H Wyman; Marguerite Kelher; Kelly M England; Nathan McLaughlin-Malaxecheberria; Carlton C Barnett; Junichi Aiboshi; Anirban Bannerjee
Journal:  J Leukoc Biol       Date:  2003-04       Impact factor: 4.962

8.  Induction of MHC class II antigens on rat bronchial epithelial cells by interferon-gamma and its effect on antigen presentation.

Authors:  T Suda; A Sato; W Sugiura; K Chida
Journal:  Lung       Date:  1995       Impact factor: 2.584

9.  GM-CSF expression by human lung microvascular endothelial cells: in vitro and in vivo findings.

Authors:  Jürgen Burg; Vera Krump-Konvalinkova; Fernando Bittinger; Charles James Kirkpatrick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-08       Impact factor: 5.464

Review 10.  TRALI risk reduction: donor and component management strategies.

Authors:  Anne F Eder; Richard J Benjamin
Journal:  J Clin Apher       Date:  2009       Impact factor: 2.821

View more
  3 in total

1.  A comparison of different methods of red blood cell leukoreduction and additive solutions on the accumulation of neutrophil-priming activity during storage.

Authors:  Michele M Loi; Marguerite Kelher; Monika Dzieciatkowska; Kirk C Hansen; Anirban Banerjee; F Bernadette West; Crystal Stanley; Matthew Briel; Christopher C Silliman
Journal:  Transfusion       Date:  2018-09-01       Impact factor: 3.157

2.  Attenuation of hemorrhage-associated lung injury by adjuvant treatment with C23, an oligopeptide derived from cold-inducible RNA-binding protein.

Authors:  Fangming Zhang; Weng-Lang Yang; Max Brenner; Ping Wang
Journal:  J Trauma Acute Care Surg       Date:  2017-10       Impact factor: 3.313

Review 3.  Risk factors, management and prevention of transfusion-related acute lung injury: a comprehensive update.

Authors:  Susan A Kuldanek; Marguerite Kelher; Christopher C Silliman
Journal:  Expert Rev Hematol       Date:  2019-07-16       Impact factor: 2.929

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.